Reference health
Cannabinoids and Neuroprotection in Basal Ganglia Disorders
74/74 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 74 checked references that resolve
resolves10.1007/BF03349186
Serum resistin increases in a postprandial state during liquid meal challenge test in healthy human subjects
resolves10.1016/j.ejphar.2003.08.101
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders
resolves10.1016/S0009-3084(00)00193-6
The endocannabinoid system: a physiological perspective on its role in psychomotor control
resolves10.1002/syn.10054
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
resolves10.1046/j.1471-4159.2003.01595.x
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
resolves10.1016/j.nbd.2004.10.015
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism
resolves10.1016/j.brainres.2005.12.014
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
resolves10.1016/j.tips.2006.11.001
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
resolves10.1007/BF02562333
Formation of<i>N</i>‐acyl‐phosphatidylethanolamine and<i>N</i>‐acylethanolamine (including anandamide) during glutamate‐induced neurotoxicity
resolves10.1046/j.1471-4159.2001.00542.x
Anandamide, but not 2‐arachidonoylglycerol, accumulates during <i>in vivo</i> neurodegeneration
resolves10.1126/science.1088208
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
resolves10.1523/JNEUROSCI.22-16-06900.2002
Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission
resolves10.1161/01.STR.0000023491.63693.18
Release of Fatty Acid Amides in a Patient With Hemispheric Stroke
resolves10.1523/JNEUROSCI.21-22-08765.2001
Exogenous Anandamide Protects Rat Brain against Acute Neuronal Injury<i>In Vivo</i>
resolves10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P
CB1 cannabinoid receptor induction in experimental stroke
resolves10.1523/JNEUROSCI.23-35-11136.2003
Cannabinoid CB<sub>2</sub>Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains
resolves10.1523/JNEUROSCI.23-10-04127.2003
Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against<i>In Vivo</i>Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases
resolves10.1124/mol.54.3.459
Cannabinoid Receptor Agonists Protect Cultured Rat Hippocampal Neurons from Excitotoxicity
resolves10.1016/S0304-3940(01)02065-1
Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity
resolves10.1523/JNEUROSCI.19-08-02987.1999
Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures
resolves10.1016/S0165-6147(00)01805-8
Modulation of transmitter release via presynaptic cannabinoid receptors
resolves10.1097/00001756-200305060-00007
Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate
resolves10.1046/j.1471-4159.2002.00961.x
Blockade of cannabinoid CB<sub>1</sub> receptor function protects against <i>in vivo</i> disseminating brain damage following NMDA‐induced excitotoxicity
resolves10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G
Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties
resolves10.1046/j.1471-4159.1998.70020671.x
Dual Effects of Anandamide on NMDA Receptor‐Mediated Responses and Neurotransmission
resolves10.1016/S0165-0173(02)00218-7
Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents
resolves10.1007/s001090050287
Cardiovascular actions of cannabinoids and their generation during shock
resolves10.1016/S0022-3565(24)39213-4
Effects of Cannabinoid Receptor Agonist and Antagonist Ligands on Production of Inflammatory Cytokines and Anti-Inflammatory Interleukin-10 in Endotoxemic Mice
resolves10.1523/JNEUROSCI.23-16-06470.2003
Endogenous Interleukin-1 Receptor Antagonist Mediates Anti-Inflammatory and Neuroprotective Actions of Cannabinoids in Neurons and Glia
resolves10.1046/j.0022-3042.2001.00716.x
Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1
resolves10.1016/0014-2999(95)00271-L
Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist
resolves10.1073/pnas.95.14.8268
Cannabidiol and (−)Δ
<sup>9</sup>
-tetrahydrocannabinol are neuroprotective antioxidants
resolves10.1016/S0022-3565(24)39301-2
Cannabinoids Protect Cells from Oxidative Cell Death: A Receptor-Independent Mechanism
resolves10.1016/j.brainres.2006.11.063
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties
resolves10.1111/j.1460-9568.2007.05717.x
Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid<i>in vivo</i>by mechanisms independent of the activation of cannabinoid, vanilloid TRPV<sub>1</sub>and adenosine A<sub>2A</sub>receptors
resolves10.1007/s00018-006-6242-0
Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies
resolves10.1523/JNEUROSCI.11-02-00563.1991
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study
resolves10.1016/j.neuropharm.2006.06.013
The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum
resolves10.1016/S0306-4522(00)00008-7
The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease
resolves10.1016/S0006-8993(01)03403-5
Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease
resolves10.1016/S0306-4522(00)00157-3
Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice
resolves10.1016/j.nbd.2005.03.026
Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model
resolves10.1074/jbc.M305057200
In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration
resolves10.1016/j.nbd.2003.09.013
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms
resolves10.1038/sj.bjp.0705662
Neuroprotective effects of M826, a reversible caspase‐3 inhibitor, in the rat malonate model of Huntington's disease
resolves10.1093/jnen/60.2.161
Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
resolves10.1016/S0301-0082(99)00067-2
Functional changes of the basal ganglia circuitry in Parkinson's disease
resolves10.1007/s007020200064
Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems
resolves10.1006/nbdi.1998.0220
Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders
resolves10.1016/j.nbd.2004.11.009
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
resolves10.1046/j.1471-4159.2002.00928.x
Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease
resolves10.1523/JNEUROSCI.20-16-06309.2000
Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia
The 5 references without a DOI — listed, not checked
no DOI — not checkedLastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz JJ, Brouillet E (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo: implication for Huntington’s disease. Neuroreport 15:2375–2379
no DOI — not checkedMcGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson’s disease. Adv Neurol 86:83–89
no DOI — not checkedSherer TB, Betarbet R, Greenamyre JT (2001) Pathogenesis of Parkinson’s disease. Curr Opin Investig Drugs 2:657–662
no DOI — not checkedMüller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999). Cannabis in movement disorders. Forsch Komplementmed 6:23–27
no DOI — not checkedNagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm 60:277–290
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s12035-007-0004-3"><img src="https://citestamp.com/citestamped/10.1007/s12035-007-0004-3/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s12035-007-0004-3)